The latest market report published by Credence Research, Inc. “Neuroendocrine Tumor Treatment Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025,” the global neuroendocrine tumor treatment market was valued at US$ 1,159.5 Mn in 2016, and is expected to reach US$ 1,928.9 Mn by 2025 expanding at a CAGR of 5.73 % from 2017 to 2025.
Browse the full report Neuroendocrine Tumor Treatment Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/neuroendocrine-tumor-treatment-market
Neuroendocrine tumors are clinically symptomatic and asymptomatic. The treatment regimen adopted for NETs is curative with emphasis given to control underlying symptoms and complications related to disease etiology with the progression of the disease. Surgery is considered as the first option for the treatment of NET, but as the disease is majorly asymptomatic it is diagnosed when the disease is in metastatic stage and so surgery is not the viable treatment option. Targeted therapy and somatostatin analogues have gained tremendous demand over the last decade as they control the symptoms, target biomarkers, and control the growth of cancer. Molecular targeted therapy comprising of drugs such as Everolimus and Sunitinib are considered as the first line treatment due to less side effects associated with the treatment regimen. Somatostatin analogues are preferred by surgeons for treating patients resistant to surgery and radiation therapy for treatment of neuroendocrine tumors.
Company profiles of the eminent players considered for the scope of the report gives important information regarding the existing product portfolio. Recent news coverage gives updates regarding the status of the drugs in pipeline tested for drug efficacy and safety in the clinical trials studies. Competitive landscape gives gist of the competitive nature of key players present in the neuroendocrine tumor treatment market. Top 3 countries and attractive investment proposition data gives industry investors the market trends present in the attractive markets. The market leaders engaged in manufacturing of drugs for the treatment of neuroendocrine tumors are Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc. and Tarveda Therapeutics.
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Neuroendocrine Tumor Treatment Market Portraiture
2.1.1. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2016 (Value %)
2.1.2. Global Neuroendocrine Tumor Treatment Market, by Geography, 2016 (Value %)
Chapter 3. Neuroendocrine Tumor Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Neuroendocrine Tumor Epidemiology Data (Prevalence & Incidence)
3.6. Attractive Investment Proposition, by Geography …
Chapter 6. Company Profiles
6.1. Advanced Accelerator Applications
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Dauntless Pharmaceuticals, Inc.
6.3. Exelixis, Inc.
6.4. Hutchinson Medipharma Limited
6.5. Ispen …
Download sample research report @ http://www.credenceresearch.com/sample-request/58912
Request for customization research report @ http://www.credenceresearch.com/request-for-customization/58912
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Company Name: Credence Research, Inc
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Address:105 N 1st ST #429, SAN JOSE, CA 95103 US
City: SAN JOSE
Country: United States